OPERATION: INSTITUTIONAL INVESTOR INSANITY

MI$$ION ACCOMPLI$HED

OPERATION: IX3
SUCCESSFULLY COMPLETED

LSR Institutional Shareholders Stats
Operation: IX3 Launch

- Total Shares Out Standing (millions): 13
- Market Capitalization ($ millions): $373
- Institutional Ownership: 13.3%
- Price (as of 6/27/2008) $27.45
- Number of Institutional Investors: 25
- Number of Shares Held: 1,681,403



LSR Institutional Shareholders Stats
Operation: IX3 Conclusion

- Total Shares Out Standing (millions): 13
- Market Capitalization ($ millions): $103.06
- Institutional Ownership: 11%
- Price (as of 8/13/2009) $7.72
- Morgan Stanley divestiture not reflected



LSR Financial Update

Much has been happening on the financial front as LSR/Huntingdon Life Sciences CEO, Andrew Baker, moves forward with his plans to acquire HLS and make it a privately held company. A Proxy Statement has been filed with the SEC (Securities Exchange Commission). You can read the 132 page document by clicking on "Proxy Statement" here:

LSR SEC FILINGS

A good analysis of the pending merger and proxy statement is provided by a New York Times financial blogger here:

BEHIND THE DEAL: LIFE SCIENCES

The Proxy Statement makes it abundantly clear that animal rights campaigning has had a tremendous impact on LSR/HLS' financial predicament and has caused them to have limited options for the future.

An in depth analysis was contracted by a special committee appointed by the Board of Directors and carried out by Plymouth Partners LLC. The Plymouth report cited the influence of animal rights campaigners over and over again, in relationship to investors, market makers, trading platforms, customers and suppliers.

Also of note in the Plymouth report was the fact that LSR/HLS was in imminent danger of defaulting on their long term debt and additionally that they were in imminent danger of being delisted by the NYSE Arca for failure to maintain the minimum levels of capitalization for continued listing. All in all, the report gave a very grim picture of LSR's financial position.

WHO HAS SOLD THEIR LSR SHARES

Partial Listing:
- Morgan Stanley
- Raymond James/Eagle Assets
- H Partners
- Barclays Global
- Deutsche Bank
- Spark Investments
- Wells Fargo
- Bank of New York Mellon
- Highbridge
- Numeric
- Rice Hall James
- Deere & Company
- PNC Financial Services
- Federated Investments
- ING Investments
- UBS
- Ameriprise Financial
- AIG
- AXA
- Palisade Capital Management
- Acadian Asset Management



LSR Managing Director, Brian Cass had this to say:

“During the latter part of 2008, it has at times felt like a perfect storm: the combination of a struggling economy affecting the capital markets, coupled with the strategic realignments within many of our customers...."

Get ready to take action
against LSR's Major Customers:

Check back for links to LSR/HLS' customers:

- Novartis
- Bristol-Myers Squibb
- GlaxoSmithKline
- Astra Zeneca
- Bayer
- Shering Plough
- Organon (part of Schering Plough)
- Syngenta
- Sanofi Aventis
- Merck

Or you can find links on the SHAC Global website:

HLS TOP TARGETS

Want to do more?

If you are an activist or organizer and you would like to find out about easy ways you can take action in your own city, e-mail WAR at: centcom@war-online.org

Please take action today!

W.A.R. (WIN ANIMAL RIGHTS) is an independent non-profit organization not affiliated or associated with SHAC, SHAC USA or any other group or organization and does not conduct or incite any illegal activity. The above information is not meant to incite or request any illegal actions or illegal activities of any kind. If you have any questions about the legality of any act, we encourage everyone receiving this (or the) action alert(s) to check your local laws and ordinances before proceeding to do anything.